Abstract 55P
Background
Routine methods for MSI/dMMR for CRC pts detection are PCR/IHC, however the data on the benefit of ICI in cases with discordant results is limited. The clinical validity of NGS as a promising approach for MSI detection is currently unclear.
Methods
Patients with MSI+ (PCR) or dMMR (IHC) colorectal cancer (CRC) were eligible (NCT06414304). All patients received immune checkpoint inhibitors (ICI) and had pre-treatment FFPE and liquid biopsy (LB) samples available for central MSI/dMMR testing with PCR/IHC (FFPE) and with NGS (Atlas Pro panel) (FFPE and LB).
Results
A total of 32 patients were included, 22 patients with stages II-III received ICI preoperatively, 10 – for advanced disease; 28 were available for response assessment. ORR in ITT population was 46%. Among 4 patients with discordant results (PCR vs IHC), ORR was 0% (p>0.05). In patients with MSI+ FFPE or MSI+ LB by NGS (n=23), ORR was 57% (p>0.05). Among pts with available LB (n=26), ORR was higher when LB samples were MSI+ (56%) vs MSS (25%) with p>0.05. Among MSI+ by NGS (LB) cases two were pMMR by IHC. Both cases had SD and were MSI+ by PCR and NGS (FFPE). None of the patients had MSI+ by NGS (LB) and MSS by PCR. Patients with DC had a median blood MSI burden of 0.07 (range, 0-0.77), whereas median MSI burden of pts with PD was 3.76 (range, 2.44-5.08) (p=0.03). Table: 55P
ORR by MSI analysis via different methods
| NGS (FFPE) | NGS (FFPE) | NGS (LB) | NGS (LB) | ||
| MSI | MSS | MSI | MSS | ||
| IHC (FFPE) | dMMR | 50% (n=16) | 0% (n=1) | 75% (n=12) | 33% (n=3) |
| IHC (FFPE) | pMMR | 0% (n=3) | n=0 | 0% (n=2) | 0% (n=1) |
| PCR (FFPE) | MSI | 45% (n=20) | 100% (n=1) | 44% (n=16) | 33% (n=3) |
| PCR (FFPE) | MSS | n=0 | 0% (n=1) | n=0 | 0% (n=1) |
Conclusions
Patients with MSI+ by PCR may experience different ICI benefits based on IHC status. Patients with MSI+ LB have better ORR. MSI burden analysis in pre-treatment LB samples is associated with better treatment outcomes. Further research is warranted.
Editorial acknowledgement
Clinical trial identification
NCT06414304.
Legal entity responsible for the study
The authors.
Funding
Russian Science Foundation (Grant №22-75-10154).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
15P - Germline predictors of recurrence in patients with ER-positive and HER2-negative breast cancer: A GWAS analysis of multiple cohorts totaling 10,640 patients
Presenter: Emma Turcotte
Session: Cocktail & Poster Display session
Resources:
Abstract
16P - The role of systemic immunity in locally advanced gastric cancer patients treated with neoadjuvant chemotherapy
Presenter: Chiara Molinari
Session: Cocktail & Poster Display session
Resources:
Abstract
17P - Development of an exo-miRNA panel for metastasis prediction in breast cancer
Presenter: Shafiqa Siddique
Session: Cocktail & Poster Display session
Resources:
Abstract
18P - Molecular characterization of circulating tumor cells in metastatic breast cancer using shallow whole genome sequencing
Presenter: Michela Bulfoni
Session: Cocktail & Poster Display session
Resources:
Abstract
19P - Single-cell transcriptomic and cell-cell communication profiles in breast cancer responders to chemotherapy or chemo-immunotherapy
Presenter: Marcela Carausu
Session: Cocktail & Poster Display session
Resources:
Abstract
20P - Distinctive genomic profile of lymph node profile and distant metastasis in papillary thyroid cancer
Presenter: Sara Gil-Bernabé
Session: Cocktail & Poster Display session
Resources:
Abstract
21P - Improving early cancer screening efficacy by adjusting tumor burden spectrum bias of liquid biopsy biomarkers
Presenter: Weituo Zhang
Session: Cocktail & Poster Display session
Resources:
Abstract
22P - Comparative analysis of miRNA biomarkers in liquid-based cytology and plasma for early detection of high-grade cervical intraepithelial neoplasia
Presenter: Stéphanie Calfa
Session: Cocktail & Poster Display session
Resources:
Abstract
23P - Unraveling predictive transcriptomic signatures of anti-EGFR therapy response in RAS/BRAF wild-type metastatic colorectal cancer
Presenter: Ana Regina de Abreu
Session: Cocktail & Poster Display session
Resources:
Abstract
24P - Integrated proteogenomic approach for discovering potential biomarkers in urothelial carcinoma of the bladder
Presenter: PONGSAKORN CHOOCHUEN
Session: Cocktail & Poster Display session
Resources:
Abstract